Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) GR1803 injection received conditional approval from China's National Medical Products Administration as a multiple myeloma treatment, according to a Friday disclosure on the Shanghai bourse.
The drug, which has the generic name veritumab injection, is for adult patients with relapsed or refractory multiple myeloma who have previously received at least three lines of therapy, including a proteasome inhibitor and an anti-CD38 monoclonal antibody.